Brief: Aytu Biopharma Inc - QTRLY Basic And Diluted Net Loss Per Common Share $2.15
21/02/2023 21:57
Feb 21 (Reuters) - Aytu Biopharma Inc AYTU.O :
* AYTU BIOPHARMA INC - QTRLY BASIC AND DILUTED NET LOSS PER
COMMON
SHARE $2.15
* AYTU BIOPHARMA INC - EXPECTS TO TERMINATE NT-502
DEVELOPMENT
PROGRAM AND ASSOCIATED LICENSING AGREEMENT
Further company coverage: AYTU.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aytu Biopharma
See all newsAytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales
Aytu Biopharma Inc expected to post a loss of 32 cents a share - Earnings Preview
Aytu BioPharma Q3 revenue falls amid EXXUA launch
Aytu BioPharma Q2 revenue beats expectations